Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
Go back to Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA| (NASDAQ: CVKD) | Delayed: 3.70 -0.33 (8.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.03 | 52 Week High | $ | |||
| Open | $4.05 | 52 Week Low | $ | |||
| Day High | $4.24 | P/E | N/A | |||
| Day Low | $3.70 | EPS | $ | |||
| Volume | 111,106 | |||||
